RecruitingPhase 2NCT07336147

Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma

Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma (DICER Trial): Taiwanese Gynecologic Oncology Group (TGOG) 1012

Sponsor

Chang Gung Memorial Hospital

Enrollment

45 participants

Start Date

Dec 22, 2025

Study Type

INTERVENTIONAL

Conditions

Female

Summary

Add-on dostarlimab to chemoradiation with etoposide and cisplatin and radiotherapy can improve progression-free survival (PFS) compared with historical controls who were treated with chemoradiation alone in SCNECC

Eligibility

Sex: FEMALEMin Age: 20 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a combination of three treatments — dostarlimab (an immunotherapy drug), cisplatin, and etoposide (both chemotherapy drugs) — given alongside radiation therapy for women with a rare and aggressive type of cervical cancer called small cell neuroendocrine carcinoma of the cervix (SCNECC). **You may be eligible if...** - You are female, between 20 and 70 years old - You have been newly diagnosed with SCNECC (confirmed by biopsy), at stage IB2 through IV or IB1 with lymphovascular spread - You have not yet received any treatment for this cancer - You are not pregnant or breastfeeding **You may NOT be eligible if...** - You have already received chemotherapy, radiation, or immunotherapy for this cancer - You are pregnant - You have conditions that prevent you from receiving the study treatments safely Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDostarlimab

The planned dose of dostarlimab for this study is 500 mg every 3 weeks (Q3W) during chemoimmunotherapy phase. Based on the totality of data generated in the dostarlimab development program, either 500 mg Q3W or 1000 mg Q6W is the appropriate dose of dostarlimab for adults across all indications and regardless of tumor type.